Amgen biopharma partners by acquiring Roche's rights to the neutropenia drugs filgrastim and pegfilgrastim, effective January 1, 2014.
An undisclosed price.
Filgrastim and pegfilgrastim are marketed by Amgen in the United States and Europe under the trade names Neupogen® and Neulasta®, respectively.
Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, in Eastern Europe, Latin America, Asia, the Middle East, and Africa.
Amgen said it will begin distributing and selling product “as soon as practical” in countries where the company has an existing commercial presence.
The biopharma partners expects the deal will be accretive to its earnings starting in 2014.
Japan’s Kyowa Hakko Kirin will continue to retain product rights and to market filgrastim and pegfilgrastim in parts of Asia, including China and Japan.
Report: Partnering Deals and Alliances with Amgen
Report: Partnering Deals and Alliances with Roche
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity